191 related articles for article (PubMed ID: 31009111)
1. Characteristics, risk factors and treatment reality in livedoid vasculopathy - a multicentre analysis.
Weishaupt C; Strölin A; Kahle B; Kreuter A; Schneider SW; Gerss J; Eveslage M; Drabik A; Goerge T
J Eur Acad Dermatol Venereol; 2019 Sep; 33(9):1784-1791. PubMed ID: 31009111
[TBL] [Abstract][Full Text] [Related]
2. Livedoid vasculopathy in Koreans: clinical features and response to rivaroxaban treatment.
Lee JS; Cho S
J Eur Acad Dermatol Venereol; 2020 Apr; 34(4):e176-e178. PubMed ID: 31793049
[No Abstract] [Full Text] [Related]
3. Efficacy of new low-dose oral anticoagulants in recalcitrant livedoid vasculopathy.
Furukawa F; Mizawa M; Makino T; Shimizu T
BMJ Case Rep; 2017 Jul; 2017():. PubMed ID: 28739563
[TBL] [Abstract][Full Text] [Related]
4. Anticoagulation with rivaroxaban for livedoid vasculopathy (RILIVA): a multicentre, single-arm, open-label, phase 2a, proof-of-concept trial.
Weishaupt C; Strölin A; Kahle B; Kreuter A; Schneider SW; Gerss J; Eveslage M; Drabik A; Goerge T
Lancet Haematol; 2016 Feb; 3(2):e72-9. PubMed ID: 26853646
[TBL] [Abstract][Full Text] [Related]
5. The management of livedoid vasculopathy focused on direct oral anticoagulants (DOACs): four case reports successfully treated with rivaroxaban.
Franco Marques G; Criado PR; Alves Batista Morita TC; Cajas García MS
Int J Dermatol; 2018 Jun; 57(6):732-741. PubMed ID: 29663354
[TBL] [Abstract][Full Text] [Related]
6. Treatment of Livedoid Vasculopathy With Rivaroxaban: A Potential Use of New Oral Anticoagulants for Dermatologists.
Jiménez-Gallo D; Villegas-Romero I; Rodríguez-Mateos ME; Linares-Barrios M
Actas Dermosifiliogr (Engl Ed); 2018 Apr; 109(3):278-281. PubMed ID: 29074145
[No Abstract] [Full Text] [Related]
7. Livedoid vasculopathy: an in-depth analysis using a modified Delphi approach.
Alavi A; Hafner J; Dutz JP; Mayer D; Sibbald RG; Criado PR; Senet P; Callen JP; Phillips TJ; Romanelli M; Kirsner RS
J Am Acad Dermatol; 2013 Dec; 69(6):1033-1042.e1. PubMed ID: 24028907
[TBL] [Abstract][Full Text] [Related]
8. Prevention of livedoid vasculopathy recurrence by prolonged administration of rivaroxaban.
Drerup C; Goerge T
J Eur Acad Dermatol Venereol; 2017 Dec; 31(12):e532. PubMed ID: 28609556
[No Abstract] [Full Text] [Related]
9. Livedoid vasculopathy in 75 Brazilian patients in a single-center institution: Clinical, histopathological and therapy evaluation.
Criado PR; Pagliari C; Morita TCAB; Marques GF; Pincelli TPH; Valente NYS; Garcia MSC; de Carvalho JF; Abdalla BMZ; Sotto MN
Dermatol Ther; 2021 Mar; 34(2):e14810. PubMed ID: 33496999
[TBL] [Abstract][Full Text] [Related]
10. Homeopathic treatment in resistant livedoid vasculopathy: case report.
Waisse-Priven S; Jurj G; Lima Thomaz LC; Tierno SA; Filho WL; Sos AB
Homeopathy; 2009 Jul; 98(3):165-8. PubMed ID: 19647211
[TBL] [Abstract][Full Text] [Related]
11. Rivaroxaban prevents painful cutaneous infarctions in livedoid vasculopathy.
Kerk N; Drabik A; Luger TA; Schneider SW; Goerge T
Br J Dermatol; 2013 Apr; 168(4):898-9. PubMed ID: 23106384
[No Abstract] [Full Text] [Related]
12. Livedoid vasculopathy - current aspects of diagnosis and treatment of cutaneous infarction.
Kerk N; Goerge T
J Dtsch Dermatol Ges; 2013 May; 11(5):407-10. PubMed ID: 23437985
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of intravenous immunoglobulins in livedoid vasculopathy: long-term follow-up of 11 patients.
Monshi B; Posch C; Vujic I; Sesti A; Sobotka S; Rappersberger K
J Am Acad Dermatol; 2014 Oct; 71(4):738-44. PubMed ID: 25022849
[TBL] [Abstract][Full Text] [Related]
14. Livedoid vasculopathy associated with sickle cell trait: significant improvement on aspirin treatment.
El Khoury J; Taher A; Kurban M; Kibbi AG; Abbas O
Int Wound J; 2012 Jun; 9(3):344-7. PubMed ID: 22044499
[TBL] [Abstract][Full Text] [Related]
15. Livedoid vasculopathy - A diagnostic and therapeutic challenge.
Burg MR; Mitschang C; Goerge T; Schneider SW
Front Med (Lausanne); 2022; 9():1012178. PubMed ID: 36262273
[TBL] [Abstract][Full Text] [Related]
16. Livedoid Vasculopathy Presenting in a Patient With Sickle Cell Disease.
Reagin H; Marks E; Weis S; Susa J
Am J Dermatopathol; 2018 Sep; 40(9):682-685. PubMed ID: 29533274
[TBL] [Abstract][Full Text] [Related]
17. A comprehensive review on pathogenesis, associations, clinical findings, and treatment of livedoid vasculopathy.
Seguí M; Llamas-Velasco M
Front Med (Lausanne); 2022; 9():993515. PubMed ID: 36569162
[TBL] [Abstract][Full Text] [Related]
18. Livedoid vasculopathy - a thrombotic disease.
Kerk N; Goerge T
Vasa; 2013 Sep; 42(5):317-22. PubMed ID: 23989066
[TBL] [Abstract][Full Text] [Related]
19. Atrophie blanche: is it associated with venous disease or livedoid vasculopathy?
Alavi A; Hafner J; Dutz JP; Mayer D; Sibbald RG; Criado PR; Senet P; Callen JP; Phillips TJ; Romanelli M; Kirsner RS
Adv Skin Wound Care; 2014 Nov; 27(11):518-24; quiz 525-6. PubMed ID: 25325229
[TBL] [Abstract][Full Text] [Related]
20. [Livedoid vasculopathy. Pathogenesis, diagnosis and treatment of cutaneous infarction].
Goerge T
Hautarzt; 2011 Aug; 62(8):627-34; quiz 635. PubMed ID: 21786003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
